Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size, Share, Growth, Trends, and Forecast 2030

Chronic Obstructive Pulmonary Disease (COPD) Treatment Industry Prospective:

The global chronic obstructive pulmonary disease (COPD) treatment market size was worth around USD 16.71 billion in 2022 and is predicted to grow to around USD 25.98 billion by 2030 with a compound annual growth rate (CAGR) of roughly 4.99% between 2023 and 2030.

Request Free Sample

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Overview

Chronic obstructive pulmonary disease (COPD) is a lung-related chronic medical condition. It results in restricted airflow in the lungs. The most common types of COPD that are widely recorded globally are chronic bronchitis and emphysema. In most cases, both conditions occur simultaneously but the intensity of the medical issue may vary depending on several factors. Common symptoms associated with chronic obstructive pulmonary disease are the formation of mucus, frequent coughing, difficulty in breathing, and wheezing. Apart from these symptoms and the discomfort associated with COPD, the occurrence of the medical condition leads to the patient being at a higher risk of contracting other diseases such as lung cancer and heart conditions.

The primary cause of COPD is generally considered long-term exposure to harmful gasses. It is a treatable condition but if left unchecked, the symptoms may intensify with time. The most commonly adopted treatment involves getting away from exposure to toxic content such as quitting smoking. However, some patients are also required to consume tablets or use inhalers for comfortable breathing. In certain cases, the patient may have to undergo an operational procedure such as a lung transplant.

Key Insights:

• As per the analysis shared by our research analyst, the global chronic obstructive pulmonary disease (COPD) treatment market is estimated to grow annually at a CAGR of around 4.99% over the forecast period (2023-2030)
• In terms of revenue, the global chronic obstructive pulmonary disease (COPD) treatment market size was valued at around USD 16.71 billion in 2022 and is projected to reach USD 25.98 billion, by 2030.
• The chronic obstructive pulmonary disease (COPD) treatment market is projected to grow at a significant rate due to the growing smoking addiction among the general population
• Based on type segmentation, emphysema and chronic bronchitis were predicted to show maximum market share in the year 2022
• Based on distribution channel segmentation, retail pharmacies were the leading segment in 2022
• On the basis of region, North America was the leading revenue generator in 2022

Request Free Sample

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Growth Drivers

Growing smoking addiction among the general population to drive market growth

The global chronic obstructive pulmonary disease (COPD) treatment market is expected to grow owing to the increasing number of people across the globe being addicted to smoking regularly. COPD is often related to frequent exposure to harmful gasses that are released during cigarette smoking. As per the World Health Organization (WHO), tobacco addiction is one of the leading forms of addiction globally. In 2020, around 22.3% of the world population was using tobacco in some form regularly. Several factors come into play that are driving the number of tobacco consumers. One of the leading reasons is the current state of variable taxation by state and federal governments related to the tobacco industry. This in turn results in affordable pricing of cigarettes. In addition to this, the social culture surrounding a person has an important influence on their habits.

For instance, children who are frequently in the vicinity of regular smokers, without proper knowledge, may find such behavior normal and continue on a similar path. Furthermore, the social media and entertainment industry is known to have a greater impact on society as opposed to other industries. Young, impressionable people are more prone to indulge in smoking habits by getting influenced by what they see, in the form of entertainment, on smart digital tools such as television and laptops.

Rising investments in the healthcare industry and improved access to healthcare may deliver a high growth rate

The world population is rising rapidly. Simultaneously, there is an urgent demand for improved healthcare access for citizens of all financial backgrounds. The increasing investments in the global healthcare sector along with rising demand for medical insurance policies have further improved the global chronic obstructive pulmonary disease (COPD) treatment market revenue.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Restraints

Absence of permanent cure for COPD to restrict market growth

As per official research, chronic obstructive pulmonary disease does not have any permanent cure. The condition, once developed, cannot be treated completely. The current treatment measures mainly aim to reduce the intensity of the symptoms or help the patients in slowing the progression rate of the disease.

Furthermore, the treatment will not be successful purely based on medicines since several lifestyle changes are also required from the patient’s end. For instance, a complete stop on smoking can be difficult for regular smokers thus impacting the global COPD treatment industry.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Opportunities

Research & development (R&D) in terms of effective medical treatment may deliver high-growth opportunities

The global chronic obstructive pulmonary disease (COPD) treatment market can expect new growth opportunities due to the increased R&D in the industry especially aimed at developing more efficient treatment methods or medicines. Global pharmaceutical companies and research institutes are increasingly focusing on mesenchymal stem cell (MSC) therapy for treating cases of COPD. These cells have proven, in several studies, that they can effectively repair damaged tissues in the lung region. Years of studies indicate that MSCs have immunomodulatory and anti-inflammatory properties. They can be used to reduce emphysema and airway inflammation that generally occurs in COPD. Some other key areas of novel interest in treatment procedures include new pharmacological options, non-invasive ventilation, and triple therapy. Treatments related to non-invasive ventilation feature the use of face masks in residential settings.

In August 2023, clinical research was conducted on the biologic medication Dupixent which was developed by Regeneron and Sanofi in a collaboration. The trial showcased positive results indicating that it could be used to treat COPD exacerbations and improve lung function effectively. Dupixent is an approved drug and is used for treating patients with eczema or allergic asthma.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Challenges

High cost of treatment and ensuring patient adherence may challenge market growth

The global chronic obstructive pulmonary disease (COPD) treatment industry's growth rate will be challenged by the high cost of treatment that is associated with COPD. In addition to being expensive, treating COPD is a long procedure and in some cases, it may last life-long.

Furthermore, the success rate of the treatment depends on the patient's adherence level. Any lapse in the treatment either from the medical professional’s or the patient's end can lead to the symptom becoming more intense. These factors are expected to challenge market growth.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Segmentation

The global chronic obstructive pulmonary disease (COPD) treatment market is segmented based on type, distribution channel, and region.

Based on type, the global market is divided into emphysema and chronic bronchitis. Both conditions are equally common in cases related to COPD. In the majority of cases, emphysema and chronic bronchitis occur at the same time. A report by the American Lung Association concluded that almost 80 to 90% of COPD cases are caused by cigarette smoking. Emphysema generally affects air sacs leading to reduced oxygen supply to the blood while chronic bronchitis affects cilia in lung airways.

Based on drug class, the global chronic obstructive pulmonary disease (COPD) treatment industry is segmented into mucokinetics, corticosteroids, combination therapy, phosphodiesterase type inhibitor, bronchodilators, and others.

Based on distribution channel, the global market is segmented into online pharmacies, retail pharmacies, and hospital pharmacies. In 2022, the highest growth rate was observed in the retail pharmacies segment. The drug-supplying units are equipped to handle the medical requirements of patients with several conditions. Furthermore, in recent times, retail pharmacies have managed to create a robust supply chain infrastructure. The improved services and digitization of retail pharmacy units have further helped segmental growth. As of 2023, CVS Health has more than 9000 retail pharmacies in the US alone.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Report Scope

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Regional Analysis

North America to emerge as the highest revenue-generating market leader

The global chronic obstructive pulmonary disease (COPD) treatment market will be led by North America during the forecast period. The growth rate is a result of higher prevalence of COPD as well as greater access to medical care. As per the Centers for Disease Control and Prevention (CDC), more than 16 million of the US population currently live with diseases caused by smoking and over 28.3 million adults are regular smokers. Another essential contributor to the regional growth rate is the widespread access to primary medical care. The majority of the regional population is covered under medical insurance. Around 75% of the Canadian population is covered under medical insurance care.

Asia-Pacific is a fast-growing region. The presence of a large population base as well as several low to middle-income economies add to the higher regional growth. Tobacco and cigarettes are extremely popular in Asian countries such as India, Pakistan, Bangladesh, and China. The diminishing air quality and rising sales of cigarettes add to the total number of patients with COPD. In addition to this, medical tourism in these regions is growing as a result of the availability of affordable medical care.

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market: Competitive Analysis

The global chronic obstructive pulmonary disease (COPD) treatment market is led by players like:

• Boehringer Ingelheim
• GlaxoSmithKline
• Sunovion Pharmaceuticals
• AstraZeneca
• Circassia Pharmaceuticals
• Novartis
• Roche
• Teva Pharmaceutical Industries
• Theravance Biopharma
• Pfizer
• Mylan N.V.
• Pearl Therapeutics
• Sanofi
• Merck & Co.
• Chiesi Farmaceutici S.p.A.

The global chronic obstructive pulmonary disease (COPD) treatment market is segmented as follows:

By Type

• Emphysema
• Chronic Bronchitis

By Drug Class

• Mucokinetics
• Corticosteroids
• Combination Therapy
• Phosphodiesterase Type Inhibitor
• Bronchodilators
• Others

By Distribution Channel

• Online Pharmacies
• Retails Pharmacies
• Hospital Pharmacies

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa